Physician profile
Mary Granger
NPI 1558473017
$19,840.91
in general payments reported to CMS, 2019-2025
12 companies · $8,218 in 2025
The $8,218 reported for 2025 was more than what 84% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,169 · 2023: $7,425 · 2024: $28.62 · 2025: $8,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,370 · Honoraria: $7,035 · Travel and Lodging: $837 · Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,370.00 |
| Honoraria | $7,035.00 |
| Travel and Lodging | $836.94 |
| Food and Beverage | $429.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hema Biologics, LLC | $8,217.77 | 2025 | Iwilfin |
| Uswm, LLC | $7,370.00 | 2023 | |
| Y-Mabs Therapeutics, INC. | $3,300.00 | 2022 | |
| Tersera Therapeutics LLC | $850.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.35 | 2023 | Livtencity |
| Tempus Ai, INC | $28.62 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.45 | 2022 | |
| Foundation Medicine, INC. | $12.72 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Granger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.